secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-070839
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026
----------------------------------------------------------------------------

- Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.
- PIPE priced at ~11% premium to March 18 close; expected to close March 21, 2024.
- Proceeds plus existing cash expected to fund operations into late 2026 and through key clinical milestones.
- ELVN-001 Phase 1a proof-of-concept data to be presented at KOL event on April 11, 2024.
- ELVN-002 combination trial first patient dosing expected in Q2 2024; Phase 1 data in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524070839/0001193125-24-070839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524070839/d759882d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-070839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer